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Intestinal cholesterol absorption is specifically inhibited by the 2-azetidinone cholesterol absorption inhibitor ezetimibe. Photoreactive ezetimibe
analogues specifically label a 145-kDa protein in the brush border membrane of enterocytes from rabbit small intestine identified as aminopeptidase
N (CD13). In zebrafish andmouse small intestinal cytosol, a heterocomplex ofMr 52 kDa between annexin II and caveolin 1 was suggested as a target
of ezetimibe. In contrast, in the cytosol and brush border membrane vesicles (BBMV) from rabbit small intestine of control animals or rabbits treated
with the nonabsorbable cholesterol absorption inhibitor AVE 5530, both annexin II and caveolin 1 were exclusively present as monomers without any
heterocomplex formation. Upon immunoprecipitation with annexin II a 52-kDa band was observed after immunostaining with annexin II antibodies,
whereas no staining of a 52-kDa band occurred with anti-caveolin 1 antibodies. Vice versa, a 52-kDa band obtained by immunoprecipitation with
caveolin 1 antibodies did not stain with annexin II-antibodies. The intensity of the 52-kDa band was dependent on the amount of antibody and was
also observed with anti-actin or anti-APN antibodies suggesting that the 52-kDa band is a biochemical artefact. After incubation of cytosol or BBMV
with radioactively labelled ezetimibe analogues, no significant amounts of the ezetimibe analogues could be detected in the immunoprecipitate with
caveolin-1 or annexin II antibodies. Photoaffinity labelling of rabbit small intestinal BBMV with ezetimibe analogues did not result in labelling of
proteins being immunoreactive with annexin II, caveolin 1 or a 52-kDa heterocomplex. These findings indicate that the rabbit small intestine does not
contain an annexin II/caveolin 1 heterocomplex as a target for ezetimibe.
© 2005 Elsevier B.V. All rights reserved.Keywords: Cholesterol absorption; Ezetimibe; Annexin II/caveolin1; Photoaffinity labelling; Brush border membrane (rabbit)1. Introduction
Intestinal absorption of cholesterol contributes significantly to
the serum cholesterol levels. The molecular mechanism of
intestinal cholesterol absorption is still not understood; the
experimental findings with specific cholesterol absorption inhibi-
tors [1,2], sterol specificity [3] and profound species differences [4]
strongly favour a protein-mediated process. A number of putative
candidates for an intestinal cholesterol transporter have been
described [5–9], but for none of these proteins has clear evidence
as an intestinal cholesterol uptake system been presented.
Ezetimibe is a cholesterol absorption inhibitor which is rapidly
absorbed in the upper small intestine; a glucuronide formed in theAbbreviations: APN, Aminopeptidase N; BBMV, Brush border membrane
vesicles; DTT, Dithiothreitol; PBS, Phosphate buffered saline
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where it exerts its pharmacological activity and inhibits intestinal
cholesterol absorption [10]. The existence of highly specific
cholesterol absorption inhibitors with clear structure–activity
relationships prompted us to identify the proteins involved in
cholesterol absorption with photoreactive analogues of the
cholesterol absorption inhibitor ezetimibe [11–13] and of
cholesterol [14]. A 145-kDa integral membrane protein was
identified as the specific binding protein for cholesterol absorption
inhibitors in the brush border membrane of small intestinal
enterocytes [11–13,15–17], whereas cholesterol specifically
interacts with a 80-kDa membrane protein [15,16] suggesting
that cholesterol uptake occurs by a complex protein machinery
rather than by a single transporter. The 145-kDa-binding protein
for cholesterol absorption inhibitors in the enterocyte brush border
membrane was identified as the ectopeptidase aminopeptidase N
[17]. Recently, the Niemann–Pick 1 like 1 protein (NPC1L1) was
described to be essential for intestinal cholesterol absorption [18]
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According to a recent report, however, NPC1L1 does not reside in
the plasma membrane but is localized intracellularly colocalizing
with the small GTPase Rab 5 [20]. Since nonabsorbable ezetimibe
analogues inhibit cholesterol absorption from the gut lumen
without getting access to the enterocyte cytosol [16], the role of
NPC1L1 as the primary target for ezetimibe is unclear due to it
absence from the brush border membrane.
Smart and coworkers have demonstrated that in the zebrafish
and the mouse, annexin II and caveolin 1 form in the cytosol a
heteromeric protein complex resistant to boiling in SDS, reducing
conditions and ether extraction [21]; ezetimibe was able to disrupt
this heterocomplex by directly interacting with caveolin 1 and
consequently the authors have suggested that the annexin II/
caveolin 1 complex is a target of ezetimibe regulating intestinal
cholesterol transport [21]. On the other hand, nonabsorbable
ezetimibe analogues like AVE5530 or S6130, act exclusively from
the intestinal lumen and do not reach the enterocyte cytosol, but are
equipotent or even more potent than ezetimibe [17]. We therefore
investigated whether an annexin II/caveolin 1 complex contributes
to the molecular action of 2-azetidinone cholesterol absorption
inhibitors in rabbit small intestine. In the present paper, we
demonstrate that ezetimibe (analogues) neither bind directly to
caveolin 1 nor annexin II nor that an annexin II/caveolin 1
heterocomplex exists in the brush border membrane or cytoplasm
of rabbit small intestinal enterocytes thereby excluding such a
complex as a primary target for ezetimibe.
2. Materials and methods
2.1. Materials
The cholesterol absorption inhibitors AVE 5530, ezetimibe, C-5, [3H]C-2
(specific radioactivity 3.41 Ci/mmol), [3H]ezetimibe (Asp=21.102 Ci/mmol)
and [3H]C-6 (Asp=1.22 Ci/mmol) (Fig. 6) were synthesized at Aventis Pharma
Deutschland GmbH according to published procedures [12,13,22]. Triton X-
100, acrylamide, N,N′-bismethylene acrylamide and Serva Blue R 250 were
from Serva (Heidelberg, Germany). Marker proteins for the determination of
molecular masses (“See Blue”, “Multi Mark”) were from Invitrogen (Karlsruhe,
Germany). Nonidet P40 and deoxycholate were from Sigma (Munich,
Germany). Streptavidin Sepharose and protein A-Sepharose were from
Amersham Biosciences whereas scintillator Quickszint 501 and tissue
solubilizer Biolute S were from Zinsser Analytic GmbH (Frankfurt, Germany).
Protein was determined with a Bradford assay kit from Bio-Rad and enzymatic
activities for aminopeptidase N were measured using the Merckotest Kit 3559
(Merck KgA, Darmstadt, Germany).
2.2. Antibodies
Antibodies against rabbit aminopeptidase N were prepared as described [17].
The following commercially available antibodies were used: Anti-actin (AC40,
antibody 11003) from Abcam (Cambridge, UK), anti-annexin II (antibody
610069), and anti-caveolin 1 (antibody 610059) from BD Biosciences
(Heidelberg, Germany), whereas the conjugate between streptavidin and alkaline
phosphatase (RPN 1234) was from Amersham Biosciences.
2.3. Animals and membrane preparation
Male New Zealand White rabbits weighing 4–5 kg (Harlan Winkelmann,
Borchem, Germany) were kept on Altromin® standard diet C 2023 (Altromin®,
Lage, Germany) ad libitum. To investigate the effect of cholesterol absorption
inhibitors on the composition of the BBMV, rabbits were treated for 4 daysreceiving once daily by gavage 2×3 mg ezetimibe or the nonabsorbable
cholesterol absorption inhibitor AVE 5530 suspended in Tylose as vehicle or
with vehicle alone. BBMV from rabbit jejunum and ileum were prepared as
described [23] and cytosol was prepared by centrifugation of freshly prepared
jejunum or ileum homogenate at 100000×g for 60 min and was immediately
used for experiments.
2.4. Immunoprecipitation
Ileal or jejunal BBMV (60–100 μg of protein) were solubilized at 1 mg/ml in
“Lysis”-buffer [21] (50 mM Tris–HCl buffer (pH 7.2)/150 mM NaCl/1% Triton
X–100/1% deoxycholate/0.1% SDS) at 20 °C for 60 min followed by
centrifugation. Immunoprecipitation experiments were performed as follows:
solubilized BBMV-proteins in Lysis-buffer (60–100 μg of protein, 1 mg/ml) or
freshly prepared jejunal or ileal cytosol (either in phosphate buffered saline or
lysis buffer, 50–100 μg at 1 mg/ml) were incubated with anti-annexin II or anti-
caveolin antibodies (usually 2 μg) and incubated for 12 h at 4 °C. Subsequently,
10 μl of protein A-beads – suspended in lysis-buffer/30 mg/ml BSA – were
added and the samples were kept at 4 °C under stirring for 2 h. After
centrifugation, the supernatants were removed for analysis by SDS-PAGE and
the beads were washed five times with 50 mM Tris–HCl buffer (pH 7.2)/200
mM NaCl/1% Triton X-100/1% deoxycholate/0.1% SDS. The beads were
subsequently immersed in SDS-sample buffer (62.5 mM Tris/HCl (pH 6.8)/2%
SDS/100 mM DTT/10% glycerol/0.001% bromophenol blue) and after
centrifugation, the supernatants were analysed by SDS-PAGE.
2.5. Binding of [3H]labelled ezetimibe analogues to protein
components of rabbit jejunal or ileal cytosol or BBMV
In order to detect a specific binding of ezetimibe analogues to caveolin,
jejunal or ileal cytosol (40 μg of protein) at 1 mg/ml in Tris/HCl buffer (pH 7.4)/
300 mM mannitol were incubated with 0.63 μCi [3H]ezetimibe or 1 μCi of [3H]
C-6 for 2 h at 30 °C. Afterwards, 2 μg of anti-caveolin 1 antibodies in 20 μl of 10
mM Tris/HCl-buffer (pH 7.4)/300 mM mannitol were added and the samples
were kept at 4 °C for 12 h. BBMV (25–40 μg of proteins) were incubated for 2
h with the [3H]labelled ezetimibe-derivatives; after dilution with 350 μl of PBS,
membranes were collected by centrifugation and solubilized in 100 μl of Lysis-
buffer after 1 h at 4 °C. After centrifugation 2 μg of anti-caveolin 1 antibodies in
20 μl of 10 mM Tris/HCl buffer (pH 7.4)/300 mM mannitol were added to the
clear supernatant containing solubilized BBMV protein and the solution was
kept at 4 °C for 12 h. Afterwards, protein A-Sepharose-beads (10 μl) were added
and the immunoprecipitation was performed as described above. Aliquots from
each step including wash-steps were counted for radioactivity.
2.6. Photoaffinity labelling
BBMV from rabbit jejunum or ileum (100–150 μg of protein) were
incubated at 1 mg/ml with [3H]labelled ezetimibe analogues in 10 mM Tris/HCl
buffer (pH 7.4)/100 mM NaCl/100 mM mannitol for 60 min at 20°C in the dark
followed by ultraviolet radiation in a Rayonet RPR-100 photochemical reactor
equipped with 4 RPR 2543-Å lamps for 120 s (C-2, C-6, ezetimibe). For
labelling with the biotin-tagged probe C-5, 10–30 μg of protein was used and
irradiation at 254 nm was performed for 30 s Afterwards, BBMV were diluted
with 10 mM Tris/HCl buffer (pH 7.4)/300 mM mannitol/1 mM Pefabloc and
washed with this buffer 3 times followed by SDS-PAGE. For immunodetection
of labelled proteins, jejunal or ileal BBMV were photolabeled with [3H]C-2,
[3H]ezetimibe or [3H]C-6 followed by SDS-PAGE and blotting; after
immunostaining with anti-annexin II, anti-caveolin 1, anti actin or anti-APN
antibodies, the immunoreactive bands were marked and afterwards the blots
were sliced into 2 mm pieces, dissolved in tissue solubilizer Biolute S and
radioactivity was determined by liquid scintillation counting.
2.7. SDS Gel electrophoresis
SDS-PAGE was carried out in vertical stab gels (20×17×0.15 cm) using an
electrophoresis system LE 2/4 (Amersham Pharmacia Biotech, Freiburg,
Germany) with gel concentrations of 7–10.5% at a ratio of 97.2% acrylamide
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12% or 15%, Invitrogen, Groningen, The Netherlands) using an electrophoresis
system XCell II from Novex. After electrophoresis the gels were fixed in 12.5%
trichloroacetic acid followed by staining with Serva Blue R 250. For
determination of the distribution of radioactivity, individual gel lanes were cut
into 2 mm pieces, protein was hydrolyzed with 250 μl of tissue solubilizer
Biolute S and after addition of 4 ml of scintillator Quickszint 501 radioactivity
was measured by liquid scintillation counting. Western blotting and immunos-
taining was performed as described earlier [24].3. Results
3.1. Immunoprecipitation with annexin II and caveolin
1-antibodies from rabbit small intestinal BBMV and cytosol
In order to detect a heteromeric protein complex between
annexin II and caveolin 1 in the rabbit, as was found in theFig. 2. Immunoprecipitation with anti-annexin II and anti-caveolin 1 antibodies
from cytosol or solubilized BBMV from rabbit jejunum. To 60 μg of freshly
prepared cytosol (a) or solubilized BBMV (b) from rabbit jejunum (1 mg/ml), 2
μg of either anti-annexin II or caveolin 1-antibodies were added followed by
addition of protein A Sepharose beads after 12 h of incubation. After washing,
proteins were extracted from the beads with SDS-sample buffer followed by
SDS-PAGE and immunostaining: C: Control cytosol or BBMV; S: Supernatants
after 12 h of antibody addition; B: Extracts from protein A sepharose beads.
Fig. 1. Immunoblotting of cytosol and BBMV from rabbit jejunum. 5 μg of
protein of freshly prepared BBMV (a) or cytosol (b) from rabbit jejunum were
separated by SDS-PAGE followed by blotting and immunostaining with the
respective antibodies: (A) Anti-annexin II; (B) Anti-caveolin-1; (C) Anti-APN;
(D) Anti-actin.zebrafish and the mouse, freshly prepared BBMV as well as
cytosol from rabbit jejunum and ileum were analysed by
Western blotting. Fig. 1a demonstrates that in the BBMV from
rabbit jejunocytes and ileocytes (data not shown), annexin II,
caveolin 1, actin as well as aminopeptidase N were detectable
as protein bands of Mr 36 kDa (annexin II), 20 and 22 kDa
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their presence as monomeric proteins on the SDS-gels; no
indications for a heteromeric complex of Mr 52 kDa for
annexin II/caveolin 1 could be found independently on the
membrane preparation (ten different membrane preparations
with the identical isolation protocol) and the conditions of
sample preparation for SDS-PAGE. Western blot analysis ofFig. 4. Effect of ezetimibe on the 52-kDa band after immunoprecipitation with
anti-annexin II antibodies from rabbit jejunal BBMV. 40 μg of rabbit jejunal
BBMV in 10 mM Tris/HCl buffer (pH 7.4)/300 mM mannitol were incubated
without (−E) or with 250 μM ezetimibe (+E) for 4 h at 20 °C. Subsequently,
BBMV were solubilized and immunoprecipitation was performed as described
in the experimental section with 3 μg of anti-annexin II antibodies followed by
SDS-PAGE and immunostaining. C: Control BBMV; P: Pellet after solubili-
zation; S: Supernatant after 12 h of antibody addition; B: Extract from protein A
sepharose beads.
Fig. 3. Immunostaining of cytosol or BBMVof rabbit jejunum after treatment of
rabbits with the nonabsorbable cholesterol absorption inhibitor AVE 5530.
Cytosol (a) and BBMV (b) from control (C) or animals treated with the
nonabsorbable cholesterol absorption inhibitor AVE 5530 (T) were freshly
prepared and 5 μg of protein per lane were analysed by SDS-PAGE and
subsequent immunostaining with the indicated antibodies.freshly prepared cytosol (Fig. 1b) from rabbit jejunum or
ileum likewise exclusively revealed bands for the monomeric
forms of annexin II (36 kDa, lane A) or actin (43 kDa, lane
D), whereas neither a 20-kDa caveolin 1 band (lane B) nor a
145-kDa APN band (lane C) could be detected in the cytosol.
After immunostaining. with anti-caveolin-1 antibodies (Fig.
1b, lane B) or anti-APN-antibodies (Fig. 1b, lane C), however,
a 52-kDa band was detectable in the cytosol (Fig. 1b, lane C).
We therefore performed immunoprecipitation experiments
with caveolin 1 and annexin II antibodies using exactly the
conditions described by Smart et al. [21]. Fig. 2a shows that
after immunoprecipitation of rabbit jejunal cytosol with
annexin II antibodies a 52-kDa band immunoreactive with
both annexin II and caveolin 1 antibodies was detectable; after
immunoprecipitation with caveolin-1 antibodies, a very strong
52 kDa band was detectable with caveolin 1 antibodies,
whereas with annexin II antibodies no 52 kDa band could be
detected in the extract from the protein A beads. If rabbit
jejunal (or ileal) BBMV were solubilized and the solubilized
membrane proteins submitted to the identical protocol, similar
results were obtained (Fig. 2b); after immunoprecipitation with
annexin II antibodies, a strong annexin II-immunoreactive
band of 52 kDa was observed in the protein-A-bead extract,
whereas only a faint 52 kDa-band was seen after staining with
caveolin-1 antibodies. Vice versa, immunoprecipitation with
caveolin 1 antibodies produced a very strong 52 kDa caveolin
1- positive band whereas no staining of a 52-kDa band was
detectable with annexin II antibodies. It was reported that in
the zebra fish, in LDL-receptor-mutant mice or in mice fed a
Fig. 6. Structures of 2-azetidinone cholesterol absorption inhibitors. (a)
Ezetimibe; (b) Glycoside C-6; (c) Photoaffinity probe C-2; (d) Biotin-tagged
photoaffinity probe C-5.
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caveolin 1 complex [21]. Treatment of rabbits with ezetimibe
or the nonabsorbable highly potent cholesterol absorption
inhibitor AVE 5530 had no effect on the putative formation or
dissociation of an annexin II/caveolin 1-complex; in jejunal
and ileal cytosol or BBMV of untreated or drug-treated
animals, identical western blot patterns were observed with
annexin II as a 36-kDa monomer, whereas with caveolin 1
antibodies, 20 and 22 kDa bands occurred (Fig. 3). In
addition, incubation of jejunal cytosol or rabbit jejunal or ileal
BBMV with ezetimibe or AVE 5530 and subsequent
immunoprecipitation with annexin II or caveolin 1-antibodies
(after solubilization of BBMV) had no effect on theFig. 5. Influence of the amount of antibody on the intensity of the 52-kDa band.
Freshly prepared rabbit jejunal cytosol (40 μg of protein) were completed with 0,
0.2, 0.5, 1 or 2 μg of anti-annexin II antibodies followed by extraction with
protein A–sepharose beads. Aliquots of the supernatants and the protein-A-
beads extracts were analysed by SDS-PAGE and immunostaining with anti-
annexin II, anti-caveolin 1, anti-actin and anti-APN antibodies. C: Control
cytosol; S: Supernatant after 12 h of antibody incubation; B: Extract from
protein A-sepharose beads. (a) After staining with anti-annexin II-antibodies; (b)
after staining with anti-caveolin 1-antibodies; (c) after staining with anti-actin-
antibodies.
Table 1
Binding of [3H]labelled ezetimibe analogues to caveolin 1 after immunoprecipitation with anti-caveolin 1 antibodies from cytosol and BBMV from rabbit jejunum or
ileum
Protein sample Incubation Bound to protein A beads extracts
Amount (fmol) Incubated (dpm, μCi) fmol dpm % of applied amount
[3H]Ezetimibe
Cytosol-jejunum 15.85×103 8.658×105 (0.39) 3.51 157 0.022
13.78×103 7.67×105 (0.345) 1.41 66 0.01
Cytosol-ileum 15.02×103 8.70×105 (0.392) 3.56 168 0.023
BBMV-ileum 10.62×103 8.97×105 (0.404) 1.58 74 0.015
2.16×103 1.01×105 (0.045) 0.32 15 0.028
[3H]-C-6
Cytosol-jejunum 664.06 2.077×106 (0.935) b53.5 145 0.008
BBMV-ileum 258.6 8.48×105 (0.382) b8.48 23 0.0033
Freshly prepared cytosol or BBMV from rabbit jejunum or ileum were incubated with [3H]labelled ezetimibe analogues followed by immunoprecipitation with anti-
caveolin 1 antibodies.
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1-antibodies (Fig. 4).
Smart et al. reported that in the mouse annexin II forms a
heteromeric 52 kDa complex with caveolin 1 in the small
intestine whereas in mouse aorta annexin II occurs as a
monomer (21) offering the possibility that annexin II and
caveolin 1 may occur in different organs or organelles either as
monomers or as heterodimers. Western blot analysis of
homogenates from rabbit jejunum or rabbit liver, rabbit jejunal
BBMV and cytosol from small enterocytes revealed in any
case, that caveolin 1 an annexin II exist in the rabbit
exclusively as monomers; after heating of the samples in
SDS-sample buffer, a 52-kDa band occurred after caveolin 1
staining, but not after annexin II-staining excluding the
possibility that a 52-kDa heterocomplex between annexin II
and caveolin 1 is formed by the procedure of sample
preparation. The findings that with antibodies against caveolin
1 and APN, a 52-kDa band was detectable in rabbit intestinal
cytosol and that by immunoprecipitation with anti-caveolin-1
antibodies from cytosol and solubilized BBMV a caveolin 1-
immunoreactive 52 kDa band was detectable in the protein-A
bead extracts lacking immunoreactivity against annexin II
suggest the possibility of a putative artefact for the 52-kDa
band. Fig. 5a shows that the amount of the 52-kDa anti-
annexin II-positive band increased with the amount of annexin
II-antibodies added; in the cytosol control (Fig. 5a, lane C) no
52 kDa band could be observed, whereas with increasing
amounts of anti annexin II antibodies, the 52-kDa band
appeared in the protein A sepharose extract (lanes B) and the
cytosol-supernatant (lanes S). Similarly, the amount of a 52-
kDa band, immunoreactive with caveolin 1 (Fig. 5b) and actin
(Fig. 5c) showed a clear dependency on the amount of
antibody used for immunoprecipitation. Analogous resultsFig. 7. Photoaffinity labelling of rabbit jejunal BBMVwith ezetimibe-derivatives. Rab
HCl buffer (pH 7.4)/100 mM NaCl/100 mM mannitol with 4.88 μM (2.5 μCi) [3H]C
20 °C followed by ultraviolet irradiation at 254 nm for 120 s After washing, prote
nitrocellulose sheets were cut into 2 mm pieces for determination of the distribution o
10 μM of the biotin-tagged photoaffinity probe C-5 and after washing and solubili
analysed after SDS-PAGE by immunostaining with streptavidin-alkaline phosphatas
annexin II (C), actin (D) and caveolin 1 (E).were obtained with solubilized BBMV from rabbit jejunum or
ileum. In control experiments where phosphate buffered saline
was used instead of cytosol or BBMV, a 52-kDa band was also
stained in the protein A extracts with annexin II or caveolin 1
antibodies after “immunoprecipitation” with annexin II or
caveolin 1 antibodies demonstrating that the 52-kDa band was
caused by the added antibodies.
3.2. Interaction of ezetimibe (analogues) with annexin II and
caveolin 1
Since it was suggested that ezetimibe disrupts the annexin II/
caveolin 1 complex most likely through a direct interaction with
caveolin 1 [21], we investigated the binding of radiolabeled
ezetimibe and ezetimibe analogues to proteins of the brush
border membrane of rabbit small intestinal enterocytes. Either
freshly prepared cytosol from rabbit jejunocytes or ileocytes or
jejunal or ileal BBMV were incubated with radioactively
labelled ezetimibe or the ezetimibe glucoside C-6 (Fig. 6);
BBMV were subsequently solubilized and the solubilized
BBM-proteins or cytosol were subjected to immunoprecipita-
tion with caveolin 1 antibodies exactly as described [21]
followed by determination of radioactivity in the immunopre-
cipitates. Table 1 demonstrates that neither for ezetimibe nor for
the nonabsorbable glucoside C-6 a significant binding to the
caveolin 1-immunoprecipitate was detectable; after incubation
with 2–15 pmol of [3H]ezetimibe (0.3–1 μCi) 0.3–3.6 fmol
(15–168 dpm) were detectable in the caveolin 1 immunopre-
cipitate despite the high specific radioactivity of 21.1 Ci/mmol
of the probe; with the glucoside C-6 less than 0.008% of the
applicated radioactivity was found in the precipitate at the
threshold of background activity. Furthermore, indistinguish-
able low counts were found by immunoprecipitation usingbit jejunal BBMV (200 μg of protein) were incubated at 1 mg/ml in 10 mM Tris/
-2, 0.79 μM (2 μCi) [3H]ezetimibe or 13.66 μM (2 μCi) [3H]C-6 for 60 min at
ins were separated by SDS-PAGE and after blotting and immunostaining, the
f radioactivity. Rabbit jejunal BBMV (200 μg of protein) were photolabeled with
zation proteins were extracted with streptavidin beads [17]. The extracts were
e conjugate for C-5 labelled proteins (A) and with antibodies against APN (B),
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experiments were performed with solubilized BBMV-proteins
without addition of caveolin 1 antibodies but with otherwiseidentical protocol. In the immunoprecipitates (protein A bead
extract) indistinguishable low counts of [3H]ezetimibe were
found as after addition of caveolin 1 antibodies. In contrast,
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only in the bead extracts after addition of caveolin 1-antibodies.
This finding clearly shows that the low amounts of [3H]
ezetimibe found in the protein A-bead extracts were indepen-
dently on the presence of caveolin 1. Thus, these results do not
give any evidence for a specific binding of ezetimibe
(analogues) to caveolin 1.
To demonstrate a putative direct binding of ezetimibe to
caveolin 1 or annexin II we have performed photoaffinity
labelling studies using the radiolabelled ezetimibe analogues C-
2, ezetimibe, the ezetimibe glycoside C-6 as well as the biotin-
tagged ezetimibe photoaffinity probe C-5 (Fig. 6). The
suitability of ezetimibe, C-2 and ezetimibe glycoside C-6 for
direct photoaffinity labelling was demonstrated by a photo-
catalysed covalent incorporation into albumin and small
intestinal BBMV upon ultraviolet irradiation at 254 nm for 90
to 120 s using the identical setup of control experiments as for
the direct photoaffinity probe [3H]benzylpenicillin [25]. Fig. 7a
shows that the photoaffinity probe C-2 predominantly incorpo-
rated into proteins ofMr 145 kDa, 98 kDa, 62 kDa and 43 kDa as
described earlier [11]. Ezetimibe and the glucoside C-6 showed
the highest incorporation into 56 kDa proteins and the 145-kDa
protein with a weak labelling of a 28-kDa band.Western blotting
revealed that none of the radioactively labelled bands obtained
with the different ezetimibe-analogues did co-migrate with
annexin II or caveolin 1. In contrast, the 43-kDa band co-
migrated with actin and the 145-kDa band with aminopeptidase
N and the identity of these radiolabeled proteins with actin and
APNwas demonstrated by sequence analysis [17]. Additionally,
after photoaffinity labelling with radiolabeled ezetimibe photo-
affinity probes and subsequent solubilization, no radioactively
labelled proteins could be precipitated with antibodies against
annexin II or caveolin 1 (data not shown). It maybe argued, that
the lack to detect a radiolabeled caveolin 1 or annexin II band is
caused by a change in immunoreactivity of the anti-caveolin 1 or
anti-annexin II antibodies to caveolin 1 and annexin II upon
binding of ezetimibe to these proteins. Dot blot analysis of
BBMV, cytosol or jejunum homogenate being incubated with
100 μM ezetimibe did not reveal any change of immunoreac-
tivity of caveolin 1 or annexin II antibodies by the presence of
ezetimibe nor was the immunoreactivity changed in Western
blotting where ezetimibe was present throughout the renaturat-
ing, blocking and immunostaining process. Rat adipocyte
membranes contain considerable amounts of caveolin; photo-
affinity labelling of rat adipocyte membranes with radioactively
labelled C1 and C-2 or the biotin-tagged C-5 ezetimibe
analogues revealed after SDS-PAGE very strong immunoreac-
tive 19 and 21 kDa bands for caveolin 1 but no comigration or
superposition of these bands with any bands labelled by the
ezetimibe analogues. The biotin-tagged ezetimibe photoaffinity
probe C-5 can be used to isolate ezetimibe-binding proteins from
rabbit small intestinal BBMV after photoaffinity labelling and
solubilization by streptavidin–biotin affinity extraction as
demonstrated elsewhere [13,17]. The purified material showed
a prominent labelling of a 145-kDa and a 43-kDa protein by the
ezetimibe analogue C-5 (Fig. 7b, lane A), which cross-react with
anti-APN-antibodies (Fig. 7b, lane B) and anti actin-antibodies(Fig. 7b, lane D). Immunostaining with anti-annexin II
antibodies (Fig. 7b, lane C) revealed the presence of annexin
II in the purified material, whereas with anti-caveolin 1-
antibodies no caveolin 1 - protein was detectable in the
streptavidin-purified material (Fig. 7b, lane E). However, no
C-5-labelled 36 kDa (annexin II) and 20/22 kDa (caveolin 1)
bands could be detected in the streptavidin-extract after
photoaffinity labelling of rabbit jejunal BBMV with the biotin-
tagged ezetimibe photoaffinity probe C-5 (Fig. 7b, lane A). In
summary, these series of experiments clearly demonstrate that
ezetimibe or ezetimibe analogues do not directly and specifically
bind to annexin II and caveolin 1.
4. Discussion
Cholesterol absorption involves formation of mixed micelles
containing cholesterol, bile acids, fatty acids and phospholipids
followed by protein-catalysed release of monomeric cholesterol
[17,26], which is distributed into the brush border membrane
and moved to detergent-resistant microdomains from which
transport to the endoplasmic reticulum occurs [27]. By
photoaffinity labelling with photoreactive analogues of the
cholesterol absorption inhibitor ezetimibe, we identified a 145-
kDa membrane protein – sequenced as aminopeptidase N (CD
13) – as the primary target for cholesterol absorption inhibitors
in the enterocyte brush border membrane [11,15–17]. We could
demonstrate that incubation of confluent CaCo2 cells with
ezetimibe led to a strong decrease of APN-expression of the
plasma membrane suggesting that binding of ezetimibe to APN
interferes with the cellular trafficking of APN between the
plasma membrane and intracellular compartments [17]. The use
of nonabsorbable ezetimibe analogues proved that binding of
cholesterol absorption inhibitors from the lumen to APN is
sufficient to inhibit cholesterol absorption, i.e. an intracellular
target for ezetimibe (analogues) is not necessary to exert its
(their) primary pharmacological effect to block intestinal
cholesterol absorption. It is however not yet known how the
binding of cholesterol absorption inhibitors interferes with
cholesterol trafficking from the brush border membrane to
intracellular compartments. Annexins are a family of caveolin-
and phospholipid-binding proteins with an involvement in a
variety of cellular processes like membrane fusion, vesicle
transport or channel formation [28]. Annexin II is assumed to be
involved in endocytosis and secretion [29–31], and it was
demonstrated that annexin II is required for the biogenesis of
multivesicular transport intermediates destined for late endo-
somes [32]. Annexin II interacts with cholesterol and its
subcellular distribution is modulated by the cholesterol
distribution, and it was suggested that annexin II forms
cholesterol-containing platforms, which regulate the onset of
the degradation pathways in animal cells [32].
A role of annexin II for intestinal cholesterol absorption
was recently reported by Smart et al. [21]; they describe a
SDS-resistant heterocomplex formed by annexin II and
caveolin 1 in the cytosol of the intestine of the zebra fish
and partially in the mouse regulating intestinal cholesterol
transport leading the authors to conclude “that this SDS-
53W. Kramer et al. / Biochimica et Biophysica Acta 1758 (2006) 45–54resistant heterocomplex is a general feature likely to be
present in all vertebrates”. In mouse aorta however, caveolin
1 and annexin II were exclusively found as monomers [21].
In enterocytes from rabbit jejunum or ileum however, annexin
II and caveolin 1 were exclusively found as monomers; under
no circumstances a 52-kDa heterocomplex between annexin II
and caveolin 1 could be found. In addition, after treatment of
rabbits with pharmacologically active doses of ezetimibe or
nonabsorbable ezetimibe analogues like AVE 5530 no
changes in the aggregation of caveolin 1 or annexin II
occurred: caveolin 1 and annexin II were detectable
exclusively as monomers indicating the absence of a
heteromeric annexin II / caveolin 1-complex in rabbit small
intestine. If, however, cytosol or solubilized BBMV-proteins
from rabbit jejunum or ileum were submitted to the
immunoprecipitation protocol as described [21], a 52-kDa
band occurred in addition to the monomers after addition of
caveolin 1 or annexin II antibodies. After extraction with
protein A-sepharose beads, immunoreactive 52 kDa bands
were observable after immunoprecipitation with annexin II
and subsequent annexin II-staining (Fig. 2); however, no 52
kDa staining occurred with caveolin 1-antibodies. Vice versa,
after immunoprecipitation with caveolin 1-antibodies, a strong
52 kDa caveolin 1-positive band was seen whereas annexin
II-staining did not reveal a 52-kDa band. These findings
suggest that the 52-kDa band is produced by addition of the
antibodies and the intensity of the 52-kDa band increased
with the amount of antibody added. Furthermore, after
annexin II – immunoprecipitation, staining with antibodies
against actin or aminopeptidase N, also a 52-kDa band was
detectable. These findings indicate that in the rabbit the 52-
kDa band obtained by immunoprecipitation with annexin II or
caveolin 1-antibodies is a biochemical artefact, probably
produced by staining of the heavy chain of the IgG-
immunoglobulins by unspecific binding of the respective
antibody-alkaline phosphatase conjugates. After incubation of
rabbit intestinal cytosol or BBMV with radiolabeled ezetimibe
or an ezetimibe glucoside no co-precipitation with caveolin 1
was found indicating that ezetimibe derivatives do not directly
bind to caveolin 1. After photoaffinity labelling of rabbit
small intestinal BBMV or cytosol with different radiolabeled
ezetimibe analogues, no incorporation of the ezetimibe
derivatives into proteins of Mr 36 kDa or 20/22 kDa was
observed nor could labelled proteins of these molecular
masses been immunoprecipitated with antibodies against
annexin II or caveolin 1. In contrast, photoincorporation of
the ezetimibe analogues occurred into the 145-kDa and 43-
kDa proteins which were identified as aminopeptidase N and
actin, respectively [17]. From these findings, we conclude that
in the rabbit neither annexin II or caveolin 1 nor a
heteromeric annexin II–caveolin 1 complex are direct
molecular targets for cholesterol absorption inhibitors like
ezetimibe. A paper published during preparation of this
manuscript showed that caveolin-1 is not required for murine
intestinal cholesterol transport also questioning a role of
caveolin-1 as a primary target for ezetimibe [33]. It remains to
be elucidated how binding of ezetimibe to its primary targetAPN in the enterocyte brush border membrane [17] interferes
with the annexin II-regulated biogenesis of multivesicular
endosomes destined for late endosomes.
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